Compare Amgen, Inc. (AMGN) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Estee Lauder Companies Inc — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while Estee Lauder Companies Inc trades at $87.79 (market cap $31.54B). The key difference: Amgen, Inc. is far larger — about 7.2× Estee Lauder Companies Inc's market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AMGN | EL | |
|---|---|---|
Market Cap | $225.71B | $31.54B |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $119.61 |
52-Week Low | $271.18 | $67.23 |
Enterprise Value | $269.02B | $37.72B |
Dividend Yield | 2.42% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
Estée Lauder (EL) trades at $88.35, up 3.35% with a bullish technical signal and recent earnings beats. The stock shows strong institutional interest with Bank of America increasing its stake by 950.9% in Q1 2026. Despite negative net income margins, the company maintains a robust gross margin of 74.71% and has upcoming Q2 2026 earnings expected at $0.3197 per share. Recent corporate developments include a new fragrance launch and executive appointments.
The outlook remains cautiously optimistic with a consensus price target of $91.67 offering 3.8% upside potential. Key risks include declining revenue trends and negative profitability, while opportunities lie in product innovation and digital engagement. The stock faces resistance near $90-$93 levels with support at $86.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
